Skip to main content
PredictPedia
K

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Trade
Event Group
EventKALSHI

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)
|
Vol

0 contracts

|
Markets

1

Trade

Market snapshot: Oct 29, 2026, 12:00 AM UTC. Prices may have changed.

Market Price Graph

1 market tracked

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

kalshi

No data available

All Markets(1)
MarketOutcome price
What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?
Yes 50.0%

Event Overview

FDA decision on Tozorakimab on or before March 31, 2027 If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. This market will close early if the FDA issues a decision on Tozorakimab before Apr 1, 2027

Market Resolution Rules

If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Early close condition: This market will close early if the FDA issues a decision on Tozorakimab before Apr 1, 2027

Important Notes

  • Markets resolve based on official data sources specified in the rules
  • Resolution may be delayed if official data is not immediately available
  • Kalshi markets are regulated by the CFTC and follow strict resolution procedures
  • Always verify the exact resolution criteria before trading
View full terms on Kalshi

Markets (1)

Sort
KALSHIHealth
What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Early close condition: This market will close early if the FDA issues a decision on Tozorakimab before Apr 1, 2027

Yes outcome50.0%
Yes
Volume0 contracts
LiquidityN/A
End DateApr 08, 2027
View Details

Share This Event

Share on social media or embed on your website

Back to Event Group